OTC is regulated like a drug because it is a drug. We manufacture it accordingly.

The compliance landscape for OTC brands launching today.

OTC products are drugs sold without a prescription, so the compliance question starts before the first batch. FDA's OTC drug review system establishes conditions under which a category can be marketed without an individual product approval: an applicable monograph identifies the permitted active ingredients, their concentrations, dosage forms, uses, labeling conditions, and other requirements. In plain language, a monograph is the rulebook for a category. A product that fits the current conditions can follow that pathway; a product that does not may need a different regulatory route rather than simply using a familiar ingredient. The manufacturing establishment must be registered with FDA as a drug establishment and must list the drugs it manufactures, prepares, propagates, compounds, or processes as required. The finished product also needs an NDC listing, which identifies the labeler, product, and package configuration in the National Drug Code directory. An NDC listing is not FDA approval and does not replace the labeler's responsibility for the product, but it is part of the required record for an OTC launch. The Drug Facts panel then communicates the regulated information in the required format: active ingredients and their purposes, uses, warnings, directions, and inactive ingredients. Marketing copy must be consistent with those facts and cannot quietly turn a cosmetic claim into a drug claim. The 2020 CARES Act replaced the older rulemaking process for OTC monographs with an administrative order framework. It also established a user-fee program and changed how FDA can update monograph conditions, including through proposed and final orders and an administrative order process for urgent conditions. That reform did not make OTC products unregulated; it changed the mechanism used to maintain the rules. For a brand, the practical work remains the same: establish the category and claim, formulate to the applicable conditions, manufacture under the right cGMP framework, maintain the required establishment and product records, and review the label against the current requirements. Stock OTC formulas typically begin at a 5,000-unit MOQ with a 90–150 day launch window; custom OTC formulations typically begin at 10,000+ units and take 6–12 months because development, testing, and documentation are more extensive.